Moderna (MRNA) Stock Price Prediction: Analyst targets improved, but price action is still fragile
In this news:
Key takeaways
- Moderna shares fell 4.45% to $198.91 and trade below most key moving averages.
- Analyst targets are mixed, and the $164.53 consensus target sits below the current share price.
- Binance open interest rose 21.42%, but taker flow still leans bearish near support.
What happened
Moderna (MRNA) is still digesting a sharp pullback. The shares were last quoted at $198.91, down 4.45% on the day, with the 24-hour range stretching from $210.22 to $192.24. That leaves the stock just above its Bollinger lower band at $189.82, but still below the 7-day, 20-day, 50-day, 12-day EMA and 26-day EMA.
That setup matters because it shows a stock that has already de-rated from the recent peak, yet has not regained trend control. The short-term structure is still distributional, with MA7 below MA20 and price trading well under the 20-day average of $231.81.
Analyst backdrop is mixed, not uniformly bullish
The latest analyst notes point in different directions. JPMorgan raised its target to $102 from $77 while keeping an Underweight rating, citing Moderna’s analyst day, updated 2026 guidance and the company’s 2027-plus expense framework. Morgan Stanley kept an Equal-Weight rating and lifted its target to $200 from $95. Piper Sandler was more constructive, raising its target to $305 from $230 and maintaining Overweight.
Broader survey data from stockanalysis.com shows 23 analysts with a consensus Hold rating and an average price target of $164.53. That sits below the current share price, which is a reminder that the market is trading above the average analyst view even after the recent decline.
Fundamentals: the earnings profile improved, but the burden is still on execution
Moderna’s own Nov. 6 update said third-quarter revenue rose 29% to $1.3 billion, cash costs fell 10% to $1.0 billion, and the company was profitable. It also lifted full-year guidance, now expecting revenue growth of 15% to 25%, above its prior outlook of up to 10% growth versus 2025. The company also said it was tracking toward its first year of revenue growth since 2022.
That is the key fundamental change here: the market is no longer dealing with a simple post-pandemic compression story. Instead, it is judging whether Moderna can sustain revenue growth while keeping costs contained and converting pipeline progress into durable operating leverage. Piper Sandler also cited third-quarter product sales of $1.27 billion, cash of $8 billion and long-term debt of $3.19 billion, which it said should support a return to profitability in 2028.
Derivatives and positioning: participation is rising, but the tape is not clean
Binance perpetual futures show funding at 0.0014%, which is neutral, so there is no strong sign that one side is aggressively paying to stay positioned. Open interest is 12,371.79 contracts, with open interest value at $2,985,798 and a 24-hour increase of 21.42%. That is a meaningful build in positioning, but it does not tell you direction by itself.
The long/short ratios are only slightly constructive. Global accounts are 52.4% long versus 47.6% short, while top-trader accounts are 50.6% long versus 49.4% short. Against that, taker flow is still leaning bearish, with the buy/sell ratio at 0.8010 and aggressive selling pressure in the most recent hour.
Technical read: near support, not yet back in trend
The chart is stretched below trend and still vulnerable. The stock is below the 7-day SMA at $211.19, the 50-day SMA at $219.28, the 12-day EMA at $219.10 and the 26-day EMA at $222.77. The 20-day SMA at $231.81 remains a far more important ceiling than a support.
Momentum is weak but not washed out. RSI at 39.67 is neutral-to-soft, MACD is negative at -3.6722, and stochastic readings of 7.51 for %K and 6.00 for %D show the stock near the lower end of its recent range. The key pivot is $200.46. Below that, immediate support sits at $190.69, then strong support at $182.48. On the upside, immediate resistance is $208.67, with stronger resistance at $218.44.
What would change the setup
For bulls, the first task is simple: hold the $190.69 area and reclaim $200.46, then push back through $208.67. That would start to repair the short-term damage and signal that the recent pullback is becoming a consolidation rather than a breakdown.
For bears, failure to defend the lower band area around $189.82 and the nearby $190.69 support would leave $182.48 exposed. The recent build in open interest would then become a risk factor rather than a positive signal, because more position size in a weak tape can amplify downside if sellers stay in control.
Source: blockchain.news
Share the article:
Trending News & Crypto World
Latest Money News
Top Trending Cryptocurrencies on The Market
Current Price
$0.3125
Market Cap
$29.7B 1.04%
24h Volume
$273.7M
Supplies
95.0B / ∞
Current Price
$1.023
Market Cap
$27.5B 0%
24h Volume
$28.0M
Supplies
26.9B / ∞
Current Price
$68.820
Market Cap
$16.4B 0.48%
24h Volume
$790.3M
Supplies
949.8M / 1.0B
Current Price
$948.64
Market Cap
$16.2B 1.64%
24h Volume
$650.3M
Supplies
17.1M / 21.0M
Current Price
$501.84
Market Cap
$9.5B -0.48%
24h Volume
$137.5M
Supplies
18.8M / ∞
Current Price
$0.05960
Market Cap
$9.3B 0.71%
24h Volume
$384.4M
Supplies
156.8B / ∞
Current Price
$9.340
Market Cap
$8.6B 0.66%
24h Volume
$950.4K
Supplies
985.2M / ∞
Current Price
$1.000
Market Cap
$8.4B -0.39%
24h Volume
$276.6M
Supplies
8.4B / ∞
Current Price
$61.850
Market Cap
$7.3B 0.06%
24h Volume
$150.8M
Supplies
293.2M / 400.0M
Current Price
$9.230
Market Cap
$7.1B 1.08%
24h Volume
$185.7M
Supplies
1.0B / 1.0B
Current Price
$0.1547
Market Cap
$5.8B 1.17%
24h Volume
$218.3M
Supplies
45.0B / 45.0B
Current Price
$0.9843
Market Cap
$4.9B 1.99%
24h Volume
$288.4K
Supplies
10.0B / 10.0B